(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Dr. Ma currently serves as Executive Vice President, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

Watch out, Gilead and Novartis ... As any cell therapy maker knows, initial supply can make or break a CAR-T roll out and has hindered others in the past. Autolus is confident in its supply chain ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. Chris Schott has given his Buy rating due to a ...

In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $95.00. Tyler Van Buren’s rating is ...

Gilead’s Q3 sales increased 7% year-over-year, including 13% year-over-year growth for Biktarvy. The Liver Disease portfolio sales increased 4% to $733 million, and Veklury sales increased 9% ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (SNSE:GILD) from Buy to Hold. There are 2,850 funds or institutions reporting positions in Gilead ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Gilead Sciences posted higher revenue and raised its full-year outlook due to strong demand in the third quarter. The biopharmaceutical company on Wednesday reported third quarter net income of $1 ...

Gilead Sciences (GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from its COVID revenues and spurring investor anticipation for new products ...